Abstract 892MO
Background
The number of prospective matched case-controlled studies to prove the safety and efficacy of autologous stem cell transplantation (ASCT) in HIV-related lymphoma is limited.
Methods
Between January 2016 and January 2020, twelve patients with HIV-related lymphoma who have undergone ASCT were included in this prospective matched case-control study (study group, n=12). Forty eight non-HIV-infected patients were enrolled to the control group (n=48, 1:4). The median age was 34 (19-66) y.o. The underlying diseases in the study group were Hodgkin lymphoma (HL) n=7 (58,3%) and non-Hodgkin lymphoma (NHL) n=5 (41,7%), complete remission at the moment of ASCT – 66,7%. Conditioning regimen was BEAM with BCNU replacement by Bendamustine 160 mg/m2/day at D-7, D-6. HIV viral load was undetectable; the median number of CD4+ cells was 471,5 (210-715) cells/mcl; all patients were on anti-retroviral therapy (ART). The median follow up time was 16 (1-43) months.
Results
The 2-year overall survival (OS) (n=60) was 90%; 91,7% in the study group and 89,9% in the control group, and this was not significantly different between the groups (P= 0,763). Progression-free survival (PFS) at 2 years in the study group was 75%, and was not significantly different to the control group (70,8%; P=0,777). Time to progression (TTP) at 2 years was 14,6% in the study group and 16,7% in the control group (P=0,643). Complete remission at the moment of ASCT improved PFS (P =0,03) and TTP (P =0,044) in the whole group. The median time for recovery of leukocytes, neutrophils, and platelets was D+14,5 (10-25), D+17 (12-30), D+15,5 (11-31), respectively, in the study group and D+14 (10-22), D+15 (10-23), D+15 (8-31) in the control group. Neutrophil recovery was significantly delayed in study group (P=0,04). There was no difference in the rate of organ toxicity according to CTCAE. The transplant-related mortality (TRM) at 2 years was 8,3% in the study group and 6,2% in the control group (P=0,8).
Conclusions
Two-year overall survival in patients with HIV-related lymphoma was 91.7%, PFS was 75%, TTP was 14,6% and TRM was 8,3% and did not differ significantly from the control group. Only neutrophil recovery was significantly delayed after ASCT in patients with HIV-related lymphoma. Our data provide further evidence that ASCT is a safe and effective approach for patients with HIV-related lymphoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
886MO - Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)
Presenter: Pier Luigi Zinzani
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
887MO - Real-world treatment management of patients with advanced-stage classic Hodgkin lymphoma receiving front line therapy
Presenter: Abraham Avigdor
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
888MO - Effectiveness of brentuximab vedotin in relapsed/refractory classic Hodgkin lymphoma: A systematic review and meta-analysis
Presenter: Bastian von Tresckow
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
889MO - Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group
Presenter: Beatriz Nunez Garcia
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
LBA37 - A blinded, randomized, parallel group, comparative investigation of a novel device (Cooral) for cryoprevention of oral mucositis
Presenter: Java Walladbegi
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
890MO - Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL
Presenter: Eleni Tholouli
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
891MO - Role of baseline PET SUVmax in predicting early progression in follicular lymphoma (FL): A single-center retrospective analysis
Presenter: Ayushi Chauhan
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
893MO - An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma
Presenter: Yan Xie
Session: Mini Oral - Haematological malignancies
Resources:
Abstract
Slides
Webcast
Open & welcome
Presenter: Andrew Davies
Session: Mini Oral - Haematological malignancies
Resources:
Slides
Webcast
Invited Discussant 886MO, 887MO, 888MO and 889MO
Presenter: Stefan Balabanov
Session: Mini Oral - Haematological malignancies
Resources:
Slides
Webcast